Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Schuler, M; Yang, Jc; Park, K; Kim, Jh; Bennouna, J; Chen, Ym; Chouaid, C; De Marinis, F; Feng, Jf; Grossi, F; Kim, Dw; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, Vk; Planchard, D; LUX-Lung, 5 Investigators